title: The sympathetic nervous system induces a metastatic switch in primary breast cancer.
abstract: Metastasis to distant tissues is the chief driver of breast cancer-related mortality, but little is known about the systemic physiologic dynamics that regulate this process. To investigate the role of neuroendocrine activation in cancer progression, we used in vivo bioluminescence imaging to track the development of metastasis in an orthotopic mouse model of breast cancer. Stress-induced neuroendocrine activation had a negligible effect on growth of the primary tumor but induced a 30-fold increase in metastasis to distant tissues including the lymph nodes and lung. These effects were mediated by β-adrenergic signaling, which increased the infiltration of CD11b(+)F4/80(+) macrophages into primary tumor parenchyma and thereby induced a prometastatic gene expression signature accompanied by indications of M2 macrophage differentiation. Pharmacologic activation of β-adrenergic signaling induced similar effects, and treatment of stressed animals with the β-antagonist propranolol reversed the stress-induced macrophage infiltration and inhibited tumor spread to distant tissues. The effects of stress on distant metastasis were also inhibited by in vivo macrophage suppression using the CSF-1 receptor kinase inhibitor GW2580. These findings identify activation of the sympathetic nervous system as a novel neural regulator of breast cancer metastasis and suggest new strategies for antimetastatic therapies that target the β-adrenergic induction of prometastatic gene expression in primary breast cancers.
authors.affiliation: UCLA Norman Cousins Center, Semel Institute for Neuroscience and Human Behavior, Medical Plaza 300, Room 3129, Los Angeles, CA 90095, USA. esloan@ucla.edu
authors.forename: Erica K
authors.initials: EK
authors.lastname: Sloan
authors.forename: Saul J
authors.initials: SJ
authors.lastname: Priceman
authors.forename: Benjamin F
authors.initials: BF
authors.lastname: Cox
authors.forename: Stephanie
authors.initials: S
authors.lastname: Yu
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Pimentel
authors.forename: Veera
authors.initials: V
authors.lastname: Tangkanangnukul
authors.forename: Jesusa M G
authors.initials: JM
authors.lastname: Arevalo
authors.forename: Kouki
authors.initials: K
authors.lastname: Morizono
authors.forename: Breanne D W
authors.initials: BD
authors.lastname: Karanikolas
authors.forename: Lily
authors.initials: L
authors.lastname: Wu
authors.forename: Anil K
authors.initials: AK
authors.lastname: Sood
authors.forename: Steven W
authors.initials: SW
authors.lastname: Cole
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology*; D000818:Animals; D045744:Cell Line, Tumor; D005260:Female; D008264:Macrophages / Q000276:immunology; D008325:Mammary Neoplasms, Experimental / Q000276:immunology / Q000473:pathology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009362:Neoplasm Metastasis; D013312:Stress, Physiological / Q000276:immunology / Q000502:physiology*; D013564:Sympathetic Nervous System / Q000473:pathology*; D013601:T-Lymphocytes / Q000276:immunology
references.citation: Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5681-6
references.pmid: 20176930
references.citation: J Invest Dermatol. 1999 May;112(5):802-9
references.pmid: 10233775
references.citation: BMJ. 2002 Jun 15;324(7351):1420
references.pmid: 12065263
references.citation: Curr Neurovasc Res. 2008 Feb;5(1):1-12
references.pmid: 18289016
references.citation: J Biol Chem. 2007 Oct 12;282(41):29919-26
references.pmid: 17716980
references.citation: Annu Rev Neurosci. 1992;15:87-114
references.pmid: 1575451
references.citation: Rev Epidemiol Sante Publique. 2004 Feb;52(1):53-65
references.pmid: 15107693
references.citation: Int J Oncol. 2002 Jul;21(1):153-7
references.pmid: 12063562
references.citation: J Clin Oncol. 2009 Jul 20;27(21):3418-9
references.pmid: 19470918
references.citation: J Neuroimmunol. 1999 May 3;96(2):182-9
references.pmid: 10337916
references.citation: World J Surg. 2004 Mar;28(3):327-30
references.pmid: 14961184
references.citation: Cancer Causes Control. 2004 Aug;15(6):535-41
references.pmid: 15280632
references.citation: Int J Cancer. 2004 Nov 1;112(2):231-8
references.pmid: 15352035
references.citation: Brain Behav Immun. 2005 Mar;19(2):114-26
references.pmid: 15664784
references.citation: Cancer Res. 2005 Oct 15;65(20):9426-35
references.pmid: 16230406
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):6839-46
references.pmid: 18980978
references.citation: J Clin Oncol. 2006 Mar 1;24(7):1105-11
references.pmid: 16505430
references.citation: Nat Clin Pract Oncol. 2008 Aug;5(8):466-75
references.pmid: 18493231
references.citation: Nat Rev Cancer. 2006 Mar;6(3):240-8
references.pmid: 16498446
references.citation: Am J Public Health. 2000 Oct;90(10):1601-7
references.pmid: 11029995
references.citation: J Neurosci. 2007 Aug 15;27(33):8857-65
references.pmid: 17699667
references.citation: Pharmacol Rev. 2001 Mar;53(1):1-24
references.pmid: 11171937
references.citation: Cancer Cell. 2009 Aug 4;16(2):91-102
references.pmid: 19647220
references.citation: BMJ. 1992 Apr 25;304(6834):1078-81
references.pmid: 1586819
references.citation: Cancer. 2003 Sep 15;98(6):1299-308
references.pmid: 12973855
references.citation: Brain Res Bull. 1998;45(2):183-7
references.pmid: 9443838
references.citation: Am J Epidemiol. 2003 Mar 1;157(5):415-23
references.pmid: 12615606
references.citation: Cancer Cell. 2009 Aug 4;16(2):81-2
references.pmid: 19647215
references.citation: Cancer. 2003 Oct 1;98(7):1504-13
references.pmid: 14508839
references.citation: Nat Med. 2005 Mar;11(3):346-52
references.pmid: 15711560
references.citation: Cancer. 2002 Nov 15;95(10):2237-42
references.pmid: 12412179
references.citation: J Neuroimmunol. 1993 Nov-Dec;48(2):151-60
references.pmid: 8227313
references.citation: J Neuroimmunol. 1994 Sep;53(2):173-80
references.pmid: 8071431
references.citation: Arch Intern Med. 2000 Feb 14;160(3):349-53
references.pmid: 10668837
references.citation: J Immunol. 1998 Apr 1;160(7):3251-8
references.pmid: 9531281
references.citation: Breast Cancer Res. 2006;8(2):R20
references.pmid: 16608535
references.citation: J Immunol. 1998 Jul 15;161(2):610-6
references.pmid: 9670934
references.citation: Am J Physiol. 1999 May;276(5):R1461-8
references.pmid: 10233040
references.citation: Clin Cancer Res. 2003 Oct 1;9(12):4514-21
references.pmid: 14555525
references.citation: Nat Med. 2006 Aug;12(8):939-44
references.pmid: 16862152
references.citation: J Psychosom Res. 1992 Sep;36(6):531-41
references.pmid: 1640391
references.citation: Brain Behav Immun. 1994 Mar;8(1):14-23
references.pmid: 8003768
references.citation: J Interferon Cytokine Res. 2005 Jul;25(7):384-94
references.pmid: 16022583
references.citation: Int J Cancer. 1994 Aug 15;58(4):512-6
references.pmid: 8056447
references.citation: J Virol. 2006 May;80(9):4326-35
references.pmid: 16611891
references.citation: Annu Rev Pharmacol Toxicol. 1995;35:417-48
references.pmid: 7598501
references.citation: Nat Rev Cancer. 2004 Jan;4(1):71-8
references.pmid: 14708027
references.citation: Blood. 2010 Feb 18;115(7):1461-71
references.pmid: 20008303